Bertoletti A, Ferrari C Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut. 2012 Dec;61(12):1754-64. doi: 10.1136/gutjnl-2011-301073. Epub 2011 Dec 9. Review.
Bertoletti A, Kennedy PT The immune tolerant phase of chronic HBV infection: new perspectives on an old concept. Cell Mol Immunol. 2015 May;12(3):258-63. doi: 10.1038/cmi.2014.79. Epub 2014 Sep 1. Review.
Chen CJ, Wang LY, Yu MW Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J Gastroenterol Hepatol. 2000 May;15 Suppl:E3-6.
Cholongitas E, Goulis J, Akriviadis E, Papatheodoridis GV Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review. Liver Transpl. 2011 Oct;17(10):1176-90. doi: 10.1002/lt.22354. Review.
Das A, Maini MK Innate and adaptive immune responses in hepatitis B virus infection. Dig Dis. 2010;28(1):126-32. doi: 10.1159/000282075. Epub 2010 May 7. Review.
Di Paolo D, Lenci I, Trinito MO, Carbone M, Longhi C, Tisone G, Angelico M Extended double-dosage HBV vaccination after liver transplantation is ineffective, in the absence of lamivudine and prior wash-out of human Hepatitis B immunoglobulins. Dig Liver Dis. 2006 Oct;38(10):749-54. Epub 2006 Aug 17.
El Khouri M, dos Santos VA Hepatitis B: epidemiological, immunological, and serological considerations emphasizing mutation. Rev Hosp Clin Fac Med Sao Paulo. 2004 Aug;59(4):216-24. Epub 2004 Sep 9. Review.
European Association For The Study Of The Liver EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009 Feb;50(2):227-42. doi: 10.1016/j.jhep.2008.10.001. Epub 2008 Oct 29. Review.
Freitas N, Cunha C, Menne S, Gudima SO Envelope proteins derived from naturally integrated hepatitis B virus DNA support assembly and release of infectious hepatitis delta virus particles. J Virol. 2014 May;88(10):5742-54. doi: 10.1128/JVI.00430-14. Epub 2014 Mar 12.
Hoa PT, Huy NT, Thu le T, Nga CN, Nakao K, Eguchi K, Chi NH, Hoang BH, Hirayama K Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B. Antimicrob Agents Chemother. 2009 Dec;53(12):5134-40. doi: 10.1128/AAC.00276-09. Epub 2009 Sep 21.
Jeng WJ, Sheen IS, Chen YC, Hsu CW, Chien RN, Chu CM, Liaw YF Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology. 2013 Dec;58(6):1888-96. doi: 10.1002/hep.26549. Epub 2013 Oct 17.
Kim YJ, Kim K, Hwang SH, Kim SS, Lee D, Cheong JY, Cho SW Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients. Clin Mol Hepatol. 2013 Sep;19(3):300-4. doi: 10.3350/cmh.2013.19.3.300. Epub 2013 Sep 30.
Koay LB, Feng IC, Sheu MJ, Kuo HT, Lin CY, Chen JJ, Wang SL, Tang LY, Tsai SL Hepatitis B virus (HBV) core antigen-specific regulatory T cells confer sustained remission to anti-HBV therapy in chronic hepatitis B with acute exacerbation. Hum Immunol. 2011 Sep;72(9):687-98. doi: 10.1016/j.humimm.2010.11.001. Epub 2011 Jan 6.
Liaw YF, Brunetto MR, Hadziyannis S The natural history of chronic HBV infection and geographical differences. Antivir Ther. 2010;15 Suppl 3:25-33. doi: 10.3851/IMP1621. Review.
Liaw YF, Tai DI, Chen TJ, Chu CM, Huang MJ Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma. Liver. 1986 Jun;6(3):133-7.
Liaw YF, Tai DI, Chu CM, Chen TJ The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology. 1988 May-Jun;8(3):493-6.
Liaw YF Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int. 2009 Jan;29 Suppl 1:100-7. doi: 10.1111/j.1478-3231.2008.01941.x. Review.
Lo CM, Lau GK, Chan SC, Fan ST, Wong J Efficacy of a pre-S containing vaccine in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. Am J Transplant. 2007 Feb;7(2):434-9.
Lo CM, Liu CL, Chan SC, Lau GK, Fan ST Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. J Hepatol. 2005 Aug;43(2):283-7.
Marinos G, Naoumov NV, Williams R Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection. Hepatology. 1996 Nov;24(5):991-5.
McDermott AB, Cohen SB, Zuckerman JN, Madrigal JA Hepatitis B third-generation vaccines: improved response and conventional vaccine non-response--evidence for genetic basis in humans. J Viral Hepat. 1998 Nov;5 Suppl 2:9-11.
Peng G, Li S, Wu W, Sun Z, Chen Y, Chen Z Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection. Immunology. 2008 Jan;123(1):57-65. Epub 2007 Aug 31.
Raz R, Koren R, Bass D Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in adults. Isr Med Assoc J. 2001 May;3(5):328-32.
Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology. 2010 Aug;139(2):491-8. doi: 10.1053/j.gastro.2010.03.059. Epub 2010 Apr 8.
Tai DI, Lin SM, Sheen IS, Chu CM, Lin DY, Liaw YF Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology. 2009 Jun;49(6):1859-67. doi: 10.1002/hep.22878.
Tan AT, Koh S, Goh W, Zhe HY, Gehring AJ, Lim SG, Bertoletti A A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. J Hepatol. 2010 Mar;52(3):330-9. doi: 10.1016/j.jhep.2009.12.015. Epub 2010 Jan 13.
Tjwa ET, van Oord GW, Hegmans JP, Janssen HL, Woltman AM Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. J Hepatol. 2011 Feb;54(2):209-18. doi: 10.1016/j.jhep.2010.07.009. Epub 2010 Sep 6.
Wang HC, Wu HC, Chen CF, Fausto N, Lei HY, Su IJ Different types of ground glass hepatocytes in chronic hepatitis B virus infection contain specific pre-S mutants that may induce endoplasmic reticulum stress. Am J Pathol. 2003 Dec;163(6):2441-9.
Xu L, Yin W, Sun R, Wei H, Tian Z Liver type I regulatory T cells suppress germinal center formation in HBV-tolerant mice. Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):16993-8. doi: 10.1073/pnas.1306437110. Epub 2013 Oct 2.
Yu XP, Guo RY, Su ML, Ming DS, Lin CZ, Deng Y, Lin ZZ, Su ZJ Dynamic Changes of Treg and Th17 Cells and Related Cytokines Closely Correlate With the Virological and Biochemical Response in Chronic Hepatitis B Patients Undergoing Nucleos(t)ide Analogues Treatment. Hepat Mon. 2013 Dec 23;13(12):e15332. doi: 10.5812/hepatmon.15332. eCollection 2013.
Zoulim F, Durantel D, Deny P Management and prevention of drug resistance in chronic hepatitis B. Liver Int. 2009 Jan;29 Suppl 1:108-15. doi: 10.1111/j.1478-3231.2008.01939.x. Review.
Efficacy of HBV Therapeutic Vaccine in Consolidation of Nucleos(t)Ide Analogues Therapy: a Pilot Study
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.